Array BioPharma To Present At The 8th Annual JMP Securities Healthcare Conference

BOULDER, Colo., July 1, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the 8th Annual JMP Securities Healthcare Conference in New York City.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.   

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

Event:

8th Annual JMP Securities Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer

Date:

Wednesday, July 10, 2013

Time:

9:00 a.m. Eastern Time

Location:

The St. Regis, NYC, NY

Webcast:

www.arraybiopharma.com

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.  Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013.  In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia Haugeto


Array BioPharma Inc.


303-386-1193


thaugeto@arraybiopharma.com

SOURCE Array BioPharma Inc.



RELATED LINKS
http://www.arraybiopharma.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.